Search
Medpace Holdings Inc
MEDPAdd to Watchlist
590.670USD
+5.660+0.97%
Close 08-07 16:00（ET）Quotes delayed by 15 min
16.49BMarket Cap
36.41P/E TTM
Forecast
Currency: USD Updated: 2026-08-07The current earnings forecast score of Medpace Holdings Inc is 6.14, ranking 329 out of 387 in the Biotechnology & Medical Research industry. The average price target is 567.50, with a high of 655.00 and a low of 302.21.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
568.832
Target Price
-2.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Medpace Holdings Inc
MEDP
14
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Medpace Holdings Inc's expected revenue for the next quarter?
Medpace Holdings Inc's expected revenue is 714.31M.
What is Medpace Holdings Inc's price target?
Analysts forecast that Medpace Holdings Inc's price target is USD 567.50, with the highest forecast at USD 655.00 and the lowest forecast at USD 302.21.
How have Medpace Holdings IncMEDP's recent earnings per share performed?
The market expectation was USD 4.31, while Medpace Holdings IncMEDP's earnings per share (EPS) for the previous quarter was USD 4.35. EPS for the next quarter is expected at USD 4.42.
What is the analyst rating for Medpace Holdings Inc?
Based on the ratings of Medpace Holdings Inc's stock from 14 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.